Developer docs
API playgroundTry for free, no card

Search company profiles

Connext

Full company profile

uuid0003vbz

Namestring
Connext
Legal namestring
CONNEXT Co., Ltd.
Websiteurl
connext.co.kr
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Connext (코넥스트) is a privately held, clinical-stage South Korean biopharmaceutical company founded in October 2017 as a concurrent startup out of the Korea Institute of Industrial Technology (KITECH), where the founding technology in recombinant collagenase and recombinant TLR5 agonists was developed. The company operates two proprietary platform technologies built on microbial (E. coli) recombinant protein expression: a recombinant collagenase platform (lead asset CNT201; follow-on CNT202 for burn necrotic tissue removal) and a recombinant TLR5 agonist platform (CNT101/xempritolimod for acute graft-versus-host disease and acute radiation syndrome; CNT102 for immuno-oncology). Its lead asset, CNT201, is positioned as the world's first recombinant collagenase therapeutic, eliminating the hemolytic toxin contamination risk associated with the only existing approved competitor (Xiaflex) and offered in a differentiated single-vial lyophilized formulation that reconstitutes with standard water for injection.

Connext addresses unmet need across three indications with CNT201 — Dupuytren's contracture (lead indication, currently in Phase 2 in Australia), Peyronie's disease, and cellulite — and pursues a defensible "Best-in-Class" novel biologic positioning (not biosimilar) that the company asserts supports a 12-year market exclusivity path. The R&D and manufacturing backbone is an ISO 9001-certified 50L-scale pilot facility at the Daegu-Gyeongbuk Advanced Medical Complex with upstream fermenter capacity and downstream purification equipment (continuous centrifuge, ultrafiltration, pilot column controller), enabling in-house GMP manufacturing for clinical supply and future commercial product sales.

The business model is a hybrid of (1) licensing and collaboration deals with global pharmaceutical companies for CNT101 and CNT201, structured as upfront payments plus development milestones (Phase 1 through BLA submission and approval) plus ongoing royalties and sales milestones; (2) retained manufacturing and supply of finished drug product to licensing partners rather than pure technology transfer; (3) CDMO services for recombinant proteins and mRNA vaccine pDNA; and (4) direct sales of GMP-grade tissue-dissolving enzyme products (TDzyme) for research and industrial use. The customer base is exclusively B2B: global pharma licensing partners, biotech CDMO clients, and research/industrial enzyme buyers. As of early 2026 the company had not generated commercial product revenue and is funded by approximately 33.8 billion KRW (~$24–25M USD) of cumulative venture capital from Korean VCs plus a strategic investor (PharmaResearch), with a KOSDAQ technology-specialty listing targeted for 2027.

Short descriptiontext

Connext is a clinical-stage South Korean biopharmaceutical company developing recombinant protein therapeutics using microbial E. coli expression. Its lead candidate CNT201 (recombinant collagenase) targets Dupuytren's contracture, Peyronie's disease, and cellulite, while its TLR5 agonist platform addresses immuno-oncology and acute graft-versus-host disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDaegu, South Korea
HQ citystring
Daegu
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
recombinant protein therapeutics, biopharmaceutical drug development, collagenase enzyme therapy, TLR5 agonist immunomodulator, CDMO contract manufacturing
Industry3 codes
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Licensing and Collaboration Deals
TypeLicensing Royalties
Description

Connext enters into licensing deals (for CNT101) and collaboration deals (for CNT201) with overseas pharmaceutical companies for co-development and market entry. Revenue is generated through upfront payments, development milestone payments tied to clinical phases (Phase 1 through Phase 3, BLA submission, and approval), and ongoing royalties based on yearly sales plus sales milestone payments.

connext.co.kr
2Product Sales (Finished Pharmaceuticals)
TypeOne Time License
Description

Leveraging its GMP manufacturing facility, Connext manufactures and sells finished pharmaceutical products directly. The company retains manufacturing and supply roles in global partnerships, enabling product revenue beyond simple technology transfer.

connext.co.kr
3CDMO Services
TypeProfessional Services
Description

Contract development and manufacturing services for recombinant protein therapeutics and mRNA vaccine plasmid. Services include process development, scale-up, non-clinical sample manufacturing, and quality analysis for external biotech and pharma companies. Positioned as a bio-material/bio-parts revenue stream.

connext.co.kr
4Biomaterial Product Sales (TDzyme)
TypeHardware Sales
Description

Sale of GMP-grade tissue-dissolving enzyme products (TDzyme) for research and industrial applications.

connext.co.kr
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Licensing deal with upfront + milestone + royalty structure
ModelOtherBilling cadenceMulti-year contract
Notes

Deal structure: (1) Upfront payment in USD; (2) Development milestone payments across clinical phases (Phase 1, Phase 2, Phase 3, BLA submission, approval); (3) Yearly royalties in USD plus sales milestone payments. Exact figures not publicly disclosed.

connext.co.kr
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Connext is a clinical-stage biopharmaceutical company that develops and manufactures recombinant protein therapeutics using a genetically engineered E. coli expression platform. Its core offerings are the recombinant collagenase candidate CNT201 for Dupuytren's contracture, Peyronie's disease, and cellulite, and the recombinant TLR5 agonist candidate CNT101 (xempritolimod) for acute graft-versus-host disease and acute radiation syndrome. The company also offers CDMO services for recombinant protein and pDNA manufacturing and sells a GMP-grade tissue-dissolving enzyme (TDzyme).

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Connext is a clinical-stage biopharmaceutical company developing recombinant protein-based therapeutics using two platform technologies: recombinant TLR5 agonists (CNT101, CNT102) and recombinant collagenase (CNT201, CNT202). The lead product CNT201 targets Dupuytren's contracture, Peyronie's disease, and cellulite, while CNT101 addresses acute graft-versus-host disease. The company also commercializes tissue-dissolving enzyme products (TDzyme) and provides CDMO services for recombinant protein and pDNA manufacturing.

Product and service1 record
1CNT201
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-01
Description

PharmaResearch, a regenerative medicine company, entered into both a strategic equity investment and a licensing/supply agreement for CNT201 for the aesthetic indication (cellulite). The partnership combines Connext's recombinant protein technology and GMP manufacturing capability with PharmaResearch's global commercialization network and aesthetic medicine expertise. Connext is responsible for clinical development and manufacturing of CNT201, while PharmaResearch leads commercialization in the aesthetic field and leverages its global network for market expansion. The partnership also includes plans for open innovation and joint development of next-generation protein-based biopharmaceuticals.

2이연제약 (Y-Young Pharmaceutical)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-12-01
Description

Connext signed an MOU with Y-Young Pharmaceutical for strengthening bio-pharmaceutical CDMO business. The partnership was intended to enhance Connext's contract development and manufacturing capabilities for biologics.

connext.co.kr
3가톨릭대학교 / 서울성모병원 (The Catholic University of Korea / Seoul St. Mary's Hospital)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Connext entered into a technology licensing agreement with The Catholic University of Korea in 2020. Additionally, the company conducted R&D collaboration with Seoul St. Mary's Hospital, including a First-in-Human clinical trial for CNT101 (xempritolimod) in healthy adults at Samsung Seoul Hospital, and conducted bridging studies for CNT101 as a treatment for acute graft-versus-host disease at The Catholic University of Korea Seoul St. Mary's Hospital.

connext.co.kr
4분당서울대학교병원 K-바이오헬스 지역센터 (Bundang Seoul National University Hospital K-Bio Health Regional Center)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Connext was selected for the K-Bio Health Regional Center support program in April 2022. The program provided clinical mentoring, clinical protocol development, and clinical trial support for CNT201's global clinical development. This support contributed to successful FDA pre-IND meetings and IND approval for the CNT201 Phase 1/2 clinical trial.

connext.co.kr
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Connext was established through a concurrent entrepreneurship (겸직창업) arrangement with the Korea Institute of Industrial Technology (KIIT) in October 2017. CEO Lee Woo-jong served as Center Head of KIIT's Biomedical Production Technology Center before founding Connext, contributing recombinant collagenase and TLR5 agonist technology developed at the institute.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

PharmaResearch is Connext's strategic investor and licensing partner for CNT201 in cellulite, and is itself a regenerative-medicine specialty pharma. Included as a direct ecosystem counterpart whose commercial uptake of CNT201 directly affects Connext's economics.

2Endo International
TypeDirect peer
Description

Endo markets Xiaflex (collagenase clostridium histolyticum), the only approved collagenase for Dupuytren's contracture and Peyronie's disease — the direct incumbent competitor to Connext's CNT201 in the lead indication.

TypeBroad incumbent
Description

Sobi is a European specialty biopharma with established commercialization infrastructure in rare disease and specialty injectable therapeutics, comparable as a potential global commercialization partner/competitor for niche biologics like CNT201.

4Codiak BioSciences
TypeEmerging player
Description

Codiak developed engineered exosome-based immunomodulatory therapeutics, conceptually comparable to Connext's TLR5 agonist platform (CNT101/CNT102) in targeting innate immune pathways for oncology and inflammatory indications.

TypeRegional player
Description

Hugel is a Korean specialty biopharma focused on aesthetics and therapeutic injectables (e.g., botulinum toxin, dermal fillers). Comparable as a Korean-listed peer operating in overlapping injectable biologics/aesthetic categories.

TypeBroad incumbent
Description

Ipsen has held collagenase commercial rights in select territories and operates broadly in specialty care including injectables for musculoskeletal and urological conditions — adjacent as a larger incumbent with overlapping therapeutic categories.

TypeDirect peer
Description

MediWound develops enzymatic debridement therapeutics (e.g., NexoBrid) for burn and wound care, closely mirroring Connext's CNT202 burn necrotic tissue removal program. Both companies focus on enzyme-based biologics for tissue-dissolving indications.

8Revance Therapeutics
TypeEmerging player
Description

Revance develops innovative injectable therapeutics (e.g., DaxibotulinumtoxinA) for aesthetic and therapeutic indications, directly comparable in the cellulite/aesthetics overlap with Connext's CNT201 cellulite program pursued via PharmaResearch.

TypeDirect peer
Description

Anika commercializes hyaluronic acid-based and enzyme-based injectable therapeutics for joint health and orthopedic indications. It shares with Connext the recombinant/injectable biologics platform focus and US/EU commercialization footprint.

TypeDirect peer
Description

Halozyme develops recombinant human hyaluronidase and other enzyme-based biologic therapeutics using proprietary platform technology. Like Connext, it leverages recombinant enzyme/protein engineering for injectable therapeutics and pursues licensing and co-development with major pharma — the closest comparable by platform and business model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Connext

Biopharmaceutical Therapeuticsconnext.co.kr

Connext is a clinical-stage South Korean biopharmaceutical company developing recombinant protein therapeutics using microbial E. coli expression. Its lead candidate CNT201 (recombinant collagenase) targets Dupuytren's contracture, Peyronie's disease, and cellulite, while its TLR5 agonist platform addresses immuno-oncology and acute graft-versus-host disease.

What Connext does

Connext (코넥스트) is a privately held, clinical-stage South Korean biopharmaceutical company founded in October 2017 as a concurrent startup out of the Korea Institute of Industrial Technology (KITECH), where the founding technology in recombinant collagenase and recombinant TLR5 agonists was developed. The company operates two proprietary platform technologies built on microbial (E. coli) recombinant protein expression: a recombinant collagenase platform (lead asset CNT201; follow-on CNT202 for burn necrotic tissue removal) and a recombinant TLR5 agonist platform (CNT101/xempritolimod for acute graft-versus-host disease and acute radiation syndrome; CNT102 for immuno-oncology). Its lead asset, CNT201, is positioned as the world's first recombinant collagenase therapeutic, eliminating the hemolytic toxin contamination risk associated with the only existing approved competitor (Xiaflex) and offered in a differentiated single-vial lyophilized formulation that reconstitutes with standard water for injection.

Connext addresses unmet need across three indications with CNT201 — Dupuytren's contracture (lead indication, currently in Phase 2 in Australia), Peyronie's disease, and cellulite — and pursues a defensible "Best-in-Class" novel biologic positioning (not biosimilar) that the company asserts supports a 12-year market exclusivity path. The R&D and manufacturing backbone is an ISO 9001-certified 50L-scale pilot facility at the Daegu-Gyeongbuk Advanced Medical Complex with upstream fermenter capacity and downstream purification equipment (continuous centrifuge, ultrafiltration, pilot column controller), enabling in-house GMP manufacturing for clinical supply and future commercial product sales.

The business model is a hybrid of (1) licensing and collaboration deals with global pharmaceutical companies for CNT101 and CNT201, structured as upfront payments plus development milestones (Phase 1 through BLA submission and approval) plus ongoing royalties and sales milestones; (2) retained manufacturing and supply of finished drug product to licensing partners rather than pure technology transfer; (3) CDMO services for recombinant proteins and mRNA vaccine pDNA; and (4) direct sales of GMP-grade tissue-dissolving enzyme products (TDzyme) for research and industrial use. The customer base is exclusively B2B: global pharma licensing partners, biotech CDMO clients, and research/industrial enzyme buyers. As of early 2026 the company had not generated commercial product revenue and is funded by approximately 33.8 billion KRW (~$24–25M USD) of cumulative venture capital from Korean VCs plus a strategic investor (PharmaResearch), with a KOSDAQ technology-specialty listing targeted for 2027.

Connext firmographics

Firmographics
Name
Connext
Legal name
CONNEXT Co., Ltd.
Website
https://connext.co.kr
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Connext is a clinical-stage South Korean biopharmaceutical company developing recombinant protein therapeutics using microbial E. coli expression. Its lead candidate CNT201 (recombinant collagenase) targets Dupuytren's contracture, Peyronie's disease, and cellulite, while its TLR5 agonist platform addresses immuno-oncology and acute graft-versus-host disease.
Ownership category
akta.pro rank

Connext industry classification

Industry
Product category
Biopharmaceutical Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Recombinant protein therapeutics
  • Biopharmaceutical drug development
  • Collagenase enzyme therapy
  • TLR5 agonist immunomodulator
  • CDMO contract manufacturing

Where Connext is headquartered

Location

Headquarters

HQ city
Daegu
HQ country
South Korea
HQ region
Asia

Offices4 records

Markets served

Connext business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Licensing and Collaboration Deals: Connext enters into licensing deals (for CNT101) and collaboration deals (for CNT201) with overseas pharmaceutical companies for co-development and market entry. Revenue is generated through upfront payments, development milestone payments tied to clinical phases (Phase 1 through Phase 3, BLA submission, and approval), and ongoing royalties based on yearly sales plus sales milestone payments.
  2. Product Sales (Finished Pharmaceuticals): Leveraging its GMP manufacturing facility, Connext manufactures and sells finished pharmaceutical products directly. The company retains manufacturing and supply roles in global partnerships, enabling product revenue beyond simple technology transfer.
  3. CDMO Services: Contract development and manufacturing services for recombinant protein therapeutics and mRNA vaccine plasmid. Services include process development, scale-up, non-clinical sample manufacturing, and quality analysis for external biotech and pharma companies. Positioned as a bio-material/bio-parts revenue stream.
  4. Biomaterial Product Sales (TDzyme): Sale of GMP-grade tissue-dissolving enzyme products (TDzyme) for research and industrial applications.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractLicensing deal with upfront + milestone + royalty structure

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Connext product offering

Product offering

Core offering

Connext is a clinical-stage biopharmaceutical company that develops and manufactures recombinant protein therapeutics using a genetically engineered E. coli expression platform. Its core offerings are the recombinant collagenase candidate CNT201 for Dupuytren's contracture, Peyronie's disease, and cellulite, and the recombinant TLR5 agonist candidate CNT101 (xempritolimod) for acute graft-versus-host disease and acute radiation syndrome. The company also offers CDMO services for recombinant protein and pDNA manufacturing and sells a GMP-grade tissue-dissolving enzyme (TDzyme).

Product overview

Connext is a clinical-stage biopharmaceutical company developing recombinant protein-based therapeutics using two platform technologies: recombinant TLR5 agonists (CNT101, CNT102) and recombinant collagenase (CNT201, CNT202). The lead product CNT201 targets Dupuytren's contracture, Peyronie's disease, and cellulite, while CNT101 addresses acute graft-versus-host disease. The company also commercializes tissue-dissolving enzyme products (TDzyme) and provides CDMO services for recombinant protein and pDNA manufacturing.

Differentiator

Problem solved

Functional benefit

Products and services

  • CNT201

Companies that use Connext

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Connext technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Connext partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • PharmaResearch (파마리서치)coreStrategic or Co-development Partner · 1 March 2026PharmaResearch, a regenerative medicine company, entered into both a strategic equity investment and a licensing/supply agreement for CNT201 for the aesthetic indication (cellulite). The partnership combines Connext's recombinant protein technology and GMP manufacturing capability with PharmaResearch's global commercialization network and aesthetic medicine expertise. Connext is responsible for clinical development and manufacturing of CNT201, while PharmaResearch leads commercialization in the aesthetic field and leverages its global network for market expansion. The partnership also includes plans for open innovation and joint development of next-generation protein-based biopharmaceuticals.
  • 이연제약 (Y-Young Pharmaceutical)minorStrategic or Co-development Partner · 1 December 2022Connext signed an MOU with Y-Young Pharmaceutical for strengthening bio-pharmaceutical CDMO business. The partnership was intended to enhance Connext's contract development and manufacturing capabilities for biologics.
  • 가톨릭대학교 / 서울성모병원 (The Catholic University of Korea / Seoul St. Mary's Hospital)minorStrategic or Co-development Partner · 1 January 2022Connext entered into a technology licensing agreement with The Catholic University of Korea in 2020. Additionally, the company conducted R&D collaboration with Seoul St. Mary's Hospital, including a First-in-Human clinical trial for CNT101 (xempritolimod) in healthy adults at Samsung Seoul Hospital, and conducted bridging studies for CNT101 as a treatment for acute graft-versus-host disease at The Catholic University of Korea Seoul St. Mary's Hospital.
  • 분당서울대학교병원 K-바이오헬스 지역센터 (Bundang Seoul National University Hospital K-Bio Health Regional Center)minorStrategic or Co-development Partner · 1 January 2022Connext was selected for the K-Bio Health Regional Center support program in April 2022. The program provided clinical mentoring, clinical protocol development, and clinical trial support for CNT201's global clinical development. This support contributed to successful FDA pre-IND meetings and IND approval for the CNT201 Phase 1/2 clinical trial.
  • 한국생산기술연구원과 겸직창업 (Korea Institute of Industrial Technology, KIIT)minorStrategic or Co-development Partner · 1 January 2022Connext was established through a concurrent entrepreneurship (겸직창업) arrangement with the Korea Institute of Industrial Technology (KIIT) in October 2017. CEO Lee Woo-jong served as Center Head of KIIT's Biomedical Production Technology Center before founding Connext, contributing recombinant collagenase and TLR5 agonist technology developed at the institute.

Scale indicators11 records

Recent moves9 records

Expansion highlights6 records

Connext competitors and assessment

Company assessment

Others

  • PharmaResearch Products: PharmaResearch is Connext's strategic investor and licensing partner for CNT201 in cellulite, and is itself a regenerative-medicine specialty pharma. Included as a direct ecosystem counterpart whose commercial uptake of CNT201 directly affects Connext's economics.

Direct peers

  • Endo International: Endo markets Xiaflex (collagenase clostridium histolyticum), the only approved collagenase for Dupuytren's contracture and Peyronie's disease — the direct incumbent competitor to Connext's CNT201 in the lead indication.
  • MediWound: MediWound develops enzymatic debridement therapeutics (e.g., NexoBrid) for burn and wound care, closely mirroring Connext's CNT202 burn necrotic tissue removal program. Both companies focus on enzyme-based biologics for tissue-dissolving indications.
  • Anika Therapeutics: Anika commercializes hyaluronic acid-based and enzyme-based injectable therapeutics for joint health and orthopedic indications. It shares with Connext the recombinant/injectable biologics platform focus and US/EU commercialization footprint.
  • Halozyme Therapeutics: Halozyme develops recombinant human hyaluronidase and other enzyme-based biologic therapeutics using proprietary platform technology. Like Connext, it leverages recombinant enzyme/protein engineering for injectable therapeutics and pursues licensing and co-development with major pharma — the closest comparable by platform and business model.

Broad incumbents

  • Swedish Orphan Biovitrum (Sobi): Sobi is a European specialty biopharma with established commercialization infrastructure in rare disease and specialty injectable therapeutics, comparable as a potential global commercialization partner/competitor for niche biologics like CNT201.
  • Ipsen: Ipsen has held collagenase commercial rights in select territories and operates broadly in specialty care including injectables for musculoskeletal and urological conditions — adjacent as a larger incumbent with overlapping therapeutic categories.

Emerging players

  • Codiak BioSciences: Codiak developed engineered exosome-based immunomodulatory therapeutics, conceptually comparable to Connext's TLR5 agonist platform (CNT101/CNT102) in targeting innate immune pathways for oncology and inflammatory indications.
  • Revance Therapeutics: Revance develops innovative injectable therapeutics (e.g., DaxibotulinumtoxinA) for aesthetic and therapeutic indications, directly comparable in the cellulite/aesthetics overlap with Connext's CNT201 cellulite program pursued via PharmaResearch.

Regional players

  • Hugel: Hugel is a Korean specialty biopharma focused on aesthetics and therapeutic injectables (e.g., botulinum toxin, dermal fillers). Comparable as a Korean-listed peer operating in overlapping injectable biologics/aesthetic categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Connext social profiles

Digital presence

Connext compliance and trust

Trust signal

Compliance1 record

Connext financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Connext leadership team

Management profile

Number of profiles

Profiles1 record

Connext funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Connext M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Connext

What does Connext do?

Connext is a clinical-stage biopharmaceutical company that develops and manufactures recombinant protein therapeutics using a genetically engineered E. coli expression platform. Its core offerings are the recombinant collagenase candidate CNT201 for Dupuytren's contracture, Peyronie's disease, and cellulite, and the recombinant TLR5 agonist candidate CNT101 (xempritolimod) for acute graft-versus-host disease and acute radiation syndrome. The company also offers CDMO services for recombinant protein and pDNA manufacturing and sells a GMP-grade tissue-dissolving enzyme (TDzyme).

Is Connext a public or private company?

Connext is a private company. It is classified as venture growth investor backed and is currently operating.

When was Connext founded?

Connext was founded in 2017. It employs 11 to 50 people.

Where is Connext based?

Connext is headquartered in Daegu, South Korea, in the Asia region.

How does Connext make money?

Four revenue lines are on record. Licensing and Collaboration Deals are the primary driver. The others are product Sales (Finished Pharmaceuticals), CDMO Services and biomaterial Product Sales (TDzyme).

Who are Connext's main competitors?

PharmaResearch Products is listed as an others. Direct peers are Endo International, MediWound, Anika Therapeutics and Halozyme Therapeutics. Broad incumbents are Swedish Orphan Biovitrum (Sobi) and Ipsen. Emerging players are Codiak BioSciences and Revance Therapeutics. Hugel is listed as a regional player.

Does Connext have an API?

No public API is recorded for Connext.

What industry is Connext in?

Connext's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors), with a secondary code of HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR Newswire APACConnext Completes Enrollment in Phase 2 Trial of CNT201 in Dupuytren's ContractureConnext has completed the enrollment of 56 participants in the Phase 2 clinical trial for CNT201 aimed at treating Dupuytren's contracture, approximately five months after the first patient's dosing. The topline Phase 2 data is expected to be reported in late 2026, with positive results potentially supporting further development of CNT201 for additional conditions like Peyronie's disease and cellulite. The trial's advancement marks a significant milestone in Connext's therapeutic efforts.YahooConnext Completes Enrollment in Phase 2 Trial of CNT201 in Dupuytren's ContractureConnext announced the completion of enrollment for all 56 participants in the Phase 2 portion of its clinical trial evaluating CNT201 for Dupuytren's contracture. The company expects to report topline data in late 2026, with positive results potentially supporting expansion into indications such as Peyronie's disease and cellulite.PR NewswireConnext Completes Enrollment in Phase 2 Trial of CNT201 in Dupuytren's ContractureConnext completed enrollment in the Phase 2 portion of its CNT201 trial for Dupuytren's contracture, enrolling all 56 planned participants about five months after first dosing. The study is now in follow-up and data analysis, with topline data expected in late 2026. Positive results could support expansion into Peyronie's disease and cellulite.스타트업엔(StartupN)Connects participates in the radiation response treatment development program under the U.S. NIH's NIAID... beginning global expansion.Conext, a South Korean biotech, will supply xempritolimod for the U.S. NIH's NIAID radiation response treatment program, partnering with Micron Biomedical. The company aims to establish U.S.-compliant production and expand into the global radiation response market. It plans to broaden indications beyond acute radiation syndrome to include radiation toxicity mitigation.PR NewswireConnext Successfully Administers First Dose of CNT201 for Dupuytren's ContractureConnext has announced the successful first administration of CNT201, its genetically recombinant collagenase therapeutic for Dupuytren's contracture, to patients in Australia as part of a Phase 1/2 clinical trial. The trial involves single administrations of four escalating dose levels across three hospitals, followed by a four-week evaluation period to assess safety, tolerability, efficacy, pharmacokinetics, and immunogenicity. Connext plans to secure proof-of-concept data by mid-next year and commence Phase 2 trials in the latter half of the year.